Kveta Kroupova,Vladimir Palicka,Jan Rosa
Kveta Kroupova
Osteoporosis is a chronic disease with high unmet medical need. It is characterized by low bone mass and deteriorated bone architecture, leading to increased risk of fragility fractures, with vertebral and hip fractures representing the hig...
Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma [0.03%]
特宾他夫松：治疗转移性脉络膜黑色素瘤的新药
Zhijian Wang,Yuhao Xie,Jing-Quan Wang et al.
Zhijian Wang et al.
On January 25, 2022, the U.S. Food and Drug Administration (FDA) approved the use of tebentafusp, a bispecific glycoprotein 100 (gp100) peptide-human leukocyte antigen (HLA)-directed CD3 T-cell activator, for the treatment of HLA-A*02:01-po...
Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer [0.03%]
新型PD-L1抑制剂舒格利单抗治疗晚期或转移性非小细胞肺癌的研究
Mandy Sakamoto,Antonio Jimeno
Mandy Sakamoto
Nearly two-thirds of patients with non-small cell lung cancer (NSCLC) have locally advanced or metastatic disease at the time of diagnosis, and many patients with early-stage disease will eventually experience metastatic recurrence. In the ...
Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis [0.03%]
secukinumab、ixekizumab、bimekizumab和brodalumab治疗银屑病和银屑病关节炎
Theodora Simopoulou,Sotirios G Tsiogkas,Efterpi Zafiriou et al.
Theodora Simopoulou et al.
In recent years, the role of interleukin-17 (IL-17) in orchestrating and manipulating proinflammatory immune responses has received special attention. It has become apparent from murine studies and clinical trials that due to its inhibitory...
Federica Pilo,Emanuele Angelucci
Federica Pilo
Mitapivat, an oral first-in-class activator of erythrocyte pyruvate kinase (PKR), was first investigated in patients with pyruvate kinase deficiency (PKD), where it was found to improve hemoglobin (Hb) concentrations in patients who did not...
Giulia Coco,Giulia Piccotti,Vito Romano et al.
Giulia Coco et al.
Dry eye disease (DED) is the most common ocular surface disorder affecting millions of people worldwide. Due to its chronic nature, the management of DED still represents a challenge in the ophthalmic practice. Nerve growth factor (NGF), wh...
Matthew W McCarthy
Matthew W McCarthy
On November 8, 2022, the United States Food and Drug Administration (FDA) issued an emergency use authorization for the interleukin-1 (IL-1) inhibitor anakinra for the treatment of patients with COVID-19 pneumonia. The authorization was spe...
The 2022 TOPRA Annual Symposium - Medical Device and IVD Symposium (October 17-19, 2022 - Vienna, Austria) [0.03%]
2022年TOPRA年度研讨会——医疗器械和体外诊断研讨会（2022年10月17-19日，奥地利维也纳）
Ana Mendez
Ana Mendez
The Organization for Professionals in Regulatory Affairs (TOPRA) celebrated its 2022 Annual Symposium, which took place in Vienna, Austria, from October 17 to 19, 2022, to discuss most relevant current issues and debate the future of health...
Xing Liu,Gao-Chuan Fang,Hao Lu et al.
Xing Liu et al.
On March 23, 2022, the U.S. Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), also known as 177Lu-PSMA-617, for the treatment of adult patients with metastatic castration-resistant prostate cancer...
Magdalena Zaborowska-Szmi,Sebastian Szmit,Maciej Krzakowski et al.
Magdalena Zaborowska-Szmi et al.
Savolitinib is a highly selective MET tyrosine kinase inhibitor. MET is involved in numerous cellular processes such as proliferation, differentiation and the formation of distant metastases. MET amplification and MET overexpression are qui...